Literature DB >> 21530550

New translational assays for preclinical modelling of cognition in schizophrenia: the touchscreen testing method for mice and rats.

T J Bussey1, A Holmes, L Lyon, A C Mar, K A L McAllister, J Nithianantharajah, C A Oomen, L M Saksida.   

Abstract

We describe a touchscreen method that satisfies a proposed 'wish-list' of desirables for a cognitive testing method for assessing rodent models of schizophrenia. A number of tests relevant to schizophrenia research are described which are currently being developed and validated using this method. These tests can be used to study reward learning, memory, perceptual discrimination, object-place associative learning, attention, impulsivity, compulsivity, extinction, simple Pavlovian conditioning, and other constructs. The tests can be deployed using a 'flexible battery' approach to establish a cognitive profile for a particular mouse or rat model. We have found these tests to be capable of detecting not just impairments in function, but enhancements as well, which is essential for testing putative cognitive therapies. New tests are being continuously developed, many of which may prove particularly valuable for schizophrenia research.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Year:  2011        PMID： 21530550      PMCID： PMC3168710          DOI： 10.1016/j.neuropharm.2011.04.011

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN： 0028-3908            Impact factor:   5.250


  198 in total

1.  Dissociation of acute and chronic intermittent phencyclidine-induced performance deficits in the 5-choice serial reaction time task: influence of clozapine.

Authors:  David M Thomson; Allan McVie; Brian J Morris; Judith A Pratt
Journal:  Psychopharmacology (Berl)       Date:  2010-09-29       Impact factor: 4.530

2.  Clinical and neurocognitive aspects of source monitoring errors in schizophrenia.

Authors:  S Vinogradov; J Willis-Shore; J H Poole; E Marten; B A Ober; G K Shenaut
Journal:  Am J Psychiatry       Date:  1997-11       Impact factor: 18.112

Review 3.  Recalling safety: cooperative functions of the ventromedial prefrontal cortex and the hippocampus in extinction.

Authors:  Kevin A Corcoran; Gregory J Quirk
Journal:  CNS Spectr       Date:  2007-03       Impact factor: 3.790

4.  Hippocampal volume in first-episode psychoses and chronic schizophrenia: a high-resolution magnetic resonance imaging study.

Authors:  D Velakoulis; C Pantelis; P D McGorry; P Dudgeon; W Brewer; M Cook; P Desmond; N Bridle; P Tierney; V Murrie; B Singh; D Copolov
Journal:  Arch Gen Psychiatry       Date:  1999-02

5.  Rare chromosomal deletions and duplications increase risk of schizophrenia.

Authors: 
Journal:  Nature       Date:  2008-07-30       Impact factor: 49.962

6.  Remediation of attentional dysfunction in rats with lesions of the medial prefrontal cortex by intra-accumbens administration of the dopamine D(2/3) receptor antagonist sulpiride.

Authors:  Marie A Pezze; Jeffrey W Dalley; Trevor W Robbins
Journal:  Psychopharmacology (Berl)       Date:  2008-11-05       Impact factor: 4.530

7.  Removal of the hippocampus and transection of the fornix produce comparable deficits on delayed non-matching to position by rats.

Authors:  J P Aggleton; A B Keith; J N Rawlins; P R Hunt; A Sahgal
Journal:  Behav Brain Res       Date:  1992-11-30       Impact factor: 3.332

Review 8.  Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia.

Authors:  Jared W Young; Susan B Powell; Victoria Risbrough; Hugh M Marston; Mark A Geyer
Journal:  Pharmacol Ther       Date:  2009-03-06       Impact factor: 12.310

9.  Elevated 3T proton MRS glutamate levels associated with poor Continuous Performance Test (CPT-0X) scores and genetic risk for schizophrenia.

Authors:  Scot E Purdon; Agitha Valiakalayil; Christopher C Hanstock; Peter Seres; Philip Tibbo
Journal:  Schizophr Res       Date:  2008-01-14       Impact factor: 4.939

Review 10.  Perception measurement in clinical trials of schizophrenia: promising paradigms from CNTRICS.

Authors:  Michael F Green; Pamela D Butler; Yue Chen; Mark A Geyer; Steven Silverstein; Jonathan K Wynn; Jong H Yoon; Vance Zemon
Journal:  Schizophr Bull       Date:  2008-11-20       Impact factor: 9.306
View more
  105 in total

1.  Intraneuronal Amyloid Beta Accumulation Disrupts Hippocampal CRTC1-Dependent Gene Expression and Cognitive Function in a Rat Model of Alzheimer Disease.

Authors:  Edward N Wilson; Andrew R Abela; Sonia Do Carmo; Simon Allard; Adam R Marks; Lindsay A Welikovitch; Adriana Ducatenzeiler; Yogita Chudasama; A Claudio Cuello
Journal:  Cereb Cortex       Date:  2017-02-01       Impact factor: 5.357

2.  Cortico-hippocampal GluN2B is essential for efficient visual-spatial discrimination learning in a touchscreen paradigm.

Authors:  Johnny A Kenton; Rebecca Castillo; Andrew Holmes; Jonathan L Brigman
Journal:  Neurobiol Learn Mem       Date:  2018-10-27       Impact factor: 2.877

Review 3.  Spontaneous object recognition and its relevance to schizophrenia: a review of findings from pharmacological, genetic, lesion and developmental rodent models.

Authors:  L Lyon; L M Saksida; T J Bussey
Journal:  Psychopharmacology (Berl)       Date:  2011-11-10       Impact factor: 4.530

Review 4.  Translational Assays for Assessment of Cognition in Rodent Models of Alzheimer's Disease and Dementia.

Authors:  A Shepherd; S Tyebji; A J Hannan; E L Burrows
Journal:  J Mol Neurosci       Date:  2016-09-16       Impact factor: 3.444

Review 5.  The NEWMEDS rodent touchscreen test battery for cognition relevant to schizophrenia.

Authors:  M Hvoslef-Eide; A C Mar; S R O Nilsson; J Alsiö; C J Heath; L M Saksida; T W Robbins; T J Bussey
Journal:  Psychopharmacology (Berl)       Date:  2015-07-24       Impact factor: 4.530

6.  Effects of the T-type calcium channel antagonist Z944 on paired associates learning and locomotor activity in rats treated with the NMDA receptor antagonist MK-801.

Authors:  Andrew J Roebuck; Wendie N Marks; Max C Liu; Nimra B Tahir; Nadine K Zabder; Terrance P Snutch; John G Howland
Journal:  Psychopharmacology (Berl)       Date:  2018-09-24       Impact factor: 4.530

Review 7.  Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome.

Authors:  Elizabeth M Berry-Kravis; Lothar Lindemann; Aia E Jønch; George Apostol; Mark F Bear; Randall L Carpenter; Jacqueline N Crawley; Aurore Curie; Vincent Des Portes; Farah Hossain; Fabrizio Gasparini; Baltazar Gomez-Mancilla; David Hessl; Eva Loth; Sebastian H Scharf; Paul P Wang; Florian Von Raison; Randi Hagerman; Will Spooren; Sébastien Jacquemont
Journal:  Nat Rev Drug Discov       Date:  2017-12-08       Impact factor: 84.694

8.  Retooling spare parts: gene duplication and cognition.

Authors:  T Grant Belgard; Daniel H Geschwind
Journal:  Nat Neurosci       Date:  2013-01       Impact factor: 24.884

Review 9.  Consideration of species differences in developing novel molecules as cognition enhancers.

Authors:  Jared W Young; J David Jentsch; Timothy J Bussey; Tanya L Wallace; Daniel M Hutcheson
Journal:  Neurosci Biobehav Rev       Date:  2012-10-12       Impact factor: 8.989

10.  Cognitive abilities on transitive inference using a novel touchscreen technology for mice.

Authors:  J L Silverman; P T Gastrell; M N Karras; M Solomon; J N Crawley
Journal:  Cereb Cortex       Date:  2013-11-28       Impact factor: 5.357
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.